Combination Chemotherapy in Treating Patients With Metastatic Colorectal Cancer
Alternation of FOLFOX6 (Oxaliplatin - Leucovorin - Fluorouracil) and FOLFIRI (Irinotecan - Leucovorin - Fluorouracil) as Second Line Treatment of Metastatic Colorectal Cancer
Sponsor: GERCOR - Multidisciplinary Oncology Cooperative Group
A PHASE2 clinical study on Colorectal Cancer, this trial is ongoing. The trial is conducted by GERCOR - Multidisciplinary Oncology Cooperative Group and has accumulated 7 data snapshots since 1999. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
7 versions recorded-
Sep 2025 — Present [monthly]
Unknown PHASE2
-
Sep 2024 — Sep 2025 [monthly]
Unknown PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Unknown PHASE2
Status: Unknown Status → Unknown
-
Jan 2021 — Jul 2024 [monthly]
Unknown Status PHASE2
-
Jun 2018 — Jan 2021 [monthly]
Unknown Status PHASE2
▶ Show 2 earlier versions
-
Feb 2018 — Jun 2018 [monthly]
Unknown Status PHASE2
-
Jan 2017 — Feb 2018 [monthly]
Unknown Status PHASE2
First recorded
Apr 1999
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- GERCOR - Multidisciplinary Oncology Cooperative Group
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Dijon, France , Le Mans, France , Lille, France , Lyon, France , Meulan-en-Yvelines, France , Montfermeil, France , Mulhouse, France , Neuilly-sur-Seine, France , Paris, France , Quincy-sous-Sénart, France and 3 more locations